(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

ConditionsEpiretinal Membrane Dry Age Related Macular Degeneration Macular Abnormalities Retina Disease Vitreoretinal Abnormality Intraretinal Hyporeflective Space Subretinal Hyporeflective Space IS/OS (Ellipsoid Zone) Disruption Retinal Pigment Epithelium (RPE) Elevation Retinal Pigment Epithelium (RPE) Atrophy

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorCarl Zeiss Meditec-Dublin CoCe

About this trial

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

Eligibility criteria

Qualifiers

Able and willing to make the required study visits.

Able and willing to give written informed consent and follow study instructions.

Able and willing to complete ophthalmic imaging.

Adults 18 years of age or older.

Disqualifiers

Inability to undergo the required tests.

Unable to give consent or follow study instructions.

Inability to fixate that precludes obtaining acceptable macula scans in the study eye.

Visudyne (verteporfin) injection within the last 48 hours in the study eye.

Trial design

Treatments tested in this trial

PathFinder 1.0 on CIRRUS HD-OCT

Treatment groups

400 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Carl Zeiss Meditec-Dublin CoCe

Lead sponsor

Source ClinicalTrials.gov